Compare EPAC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | MPLT |
|---|---|---|
| Founded | 1910 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1994 | 2025 |
| Metric | EPAC | MPLT |
|---|---|---|
| Price | $35.65 | $8.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $48.00 | $26.54 |
| AVG Volume (30 Days) | 338.6K | ★ 343.7K |
| Earning Date | 10-28-2026 | 12-03-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | 8.97 | ★ 82.39 |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $616,899,000.00 | N/A |
| Revenue This Year | $3.69 | N/A |
| Revenue Next Year | $4.91 | N/A |
| P/E Ratio | $28.81 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $32.35 | $7.46 |
| 52 Week High | $43.97 | $40.43 |
| Indicator | EPAC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 30.63 |
| Support Level | $34.24 | $7.46 |
| Resistance Level | $36.54 | $14.22 |
| Average True Range (ATR) | 0.78 | 0.58 |
| MACD | 0.10 | 0.12 |
| Stochastic Oscillator | 72.34 | 23.71 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.